Simulations Plus, Inc. ( SLP ) NASDAQ Global Select

Cena: 17.75 ( -3.32% )

Aktualizacja 07-03 22:00
NASDAQ Global Select
Branża: Medical - Healthcare Information Services
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Healthcare Information Services
Zatrudnienie: 243
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 81%
Ilość akcji: 19 967 100
Debiut giełdowy: 1997-06-18
WWW: https://www.simulations-plus.com
CEO: Mr. Shawn M. O'Connor
Adres: 42505 Tenth Street West
Siedziba: 93534-7059 Lancaster
ISIN: US8292141053
Opis firmy:

Symulacje Plus, Inc. opracowuje oprogramowanie do odkrywania i rozwoju leków do modelowania i symulacji oraz przewidywanie właściwości molekularnych z wykorzystaniem sztucznej inteligencji i technologii opartej na uczeniu maszynowym na całym świecie. Działa w czterech segmentach: Symulacje Plus, Cognigen, Dilisym i Lixoft. Firma oferuje gastrul, który symuluje wchłanianie i interakcję związków podawanych ludziom i zwierzętom; oraz produkty symulacyjne DDDPlus i Membraneplus. Zapewnia również produkty oparte na modelach mechanistycznych i matematycznych, takich jak DiLisym, oprogramowanie do farmakologii systemów ilościowych; Nafldsym; IPFSYM; Renasym; i mitosym. Ponadto firma zapewnia wchłanianie, dystrybucję, metabolizm, wydalanie i predyktor toksyczności dla programu komputerowego opartego na chemii, który przyjmuje struktury molekularne jako dane wejściowe i przewiduje ich właściwości; oraz projektant Medchem, a także produkty do modelowania i symulacji zawierające monolixsuite i pkplus. Ponadto zapewnia usługi badawcze do modelowania populacji i symulacji; Usługi szkolenia i konsultacji mające na celu przyspieszenie badań farmakometrycznych; oraz usługi konsultingowe oparte na klinicznej farmakologii w celu wsparcia zgłoszeń regulacyjnych. Firma obsługuje farmaceutyczne, biotechnologię, agrochemiczne, kosmetyki i firmy spożywcze, a także agencje akademickie i regulacyjne. Symulacje Plus, Inc. zostało włączone w 1996 roku i ma siedzibę w Lancaster w Kalifornii.

Wskaźniki finansowe
Kapitalizacja (USD) 356 970 250
Aktywa: 196 639 000
Cena: 17.75
Wskaźnik Altman Z-Score: 27.1
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: 49.3
Ilość akcji w obrocie: 81%
Średni wolumen: 450 967
Ilość akcji 20 111 000
Wskaźniki finansowe
Przychody TTM 70 013 000
Zobowiązania: 14 208 000
Przedział 52 tyg.: 16.72 - 44.33
Piotroski F-Score: 5
Umiarkowany (średnia jakość finansowa)
EPS: 0.4
P/E branży: 32.4
Beta: 0.709
Raport okresowy: 2025-07-14
WWW: https://www.simulations-plus.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Shawn M. O'Connor Chief Executive Officer 847 564 1960
Dr. Walter S. Woltosz M.A.S., M.S. Co-Founder & Chairman 80 000 1945
Mr. William Frederick Chief Operating Officer, Chief Financial Officer & Secretary 443 121 1964
Mr. John Anthony DiBella M.S. President of PBPK & Cheminformatics Solutions 399 803 1980
Ms. Jill Fiedler-Kelly M.S. President of Clinical Pharmacology & Pharmacometrics Services 393 770 1970
Dr. Brett A. Howell Ph.D. President of Quantitative Systems Pharmacology Solutions 321 667 1984
Dr. Bud Nelson J.D., Ph.D. Vice President of Corporate Counsel & Personal Data Protection Officer 0 0
Ms. Jennifer Presnell Accounting Manager 0 0
Ms. Viera Lukacova Ph.D. Chief Science Officer 0 0
Ms. Christina Hendrickson Director of Corporate Marketing 0 0
Wiadomości dla Simulations Plus, Inc.
Tytuł Treść Źródło Aktualizacja Link
Simulations Plus Releases DILIsym® 11 RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of DILIsym® 11, the latest version of its flagship quantitative systems toxicology (QST) platform. “Advancing toxicology research and improving the prediction of drug-induced liver injury (DILI) are. businesswire.com 2025-05-15 11:50:00 Czytaj oryginał (ang.)
Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced its support of the U.S. Food and Drug Administration's (FDA) recently announced roadmap for reducing animal testing through the use of new approach methodologies (NAMs). Simulations Plus has long provided the i. businesswire.com 2025-04-21 11:50:00 Czytaj oryginał (ang.)
Simulations Plus: Benefiting From FDA Modernization And AI Simulations Plus, Inc. offers AI-based software tools for drug discovery and optimization, significantly reducing R&D time and costs for pharmaceutical research. SLP's diverse software portfolio, including GastroPlus and ADMET Predictor, and consulting services position it as a comprehensive partner in biotech development. Favorable regulatory changes by the FDA towards AI and non-animal testing methods boost SLP's market potential, despite its current high valuation. seekingalpha.com 2025-04-16 12:30:00 Czytaj oryginał (ang.)
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday? The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing. benzinga.com 2025-04-11 14:44:28 Czytaj oryginał (ang.)
Simulations Plus: I See Promising Growth, But I'm Staying Neutral Simulations Plus, Inc. excels with its AI-driven biosimulation platforms, aiding drug development, but faces challenges with margin erosion and cash flow pressures. Despite strong revenue growth and promising pipeline expansions, operational inefficiencies and rising costs raise concerns about near-term profitability. Management's ability to convert backlog into profitable revenue and stabilize margins is crucial for long-term shareholder value. seekingalpha.com 2025-04-04 15:24:56 Czytaj oryginał (ang.)
SLP's Q2 Earnings Top, Sales Up Y/Y Despite Industry Headwinds Simulations Plus' fiscal Q2 2025 performance gains from its strong software solutions and services portfolio amid limited customer funding. zacks.com 2025-04-04 13:45:34 Czytaj oryginał (ang.)
Simulations Plus, Inc. (SLP) Q2 2025 Earnings Call Transcript Simulations Plus, Inc. (NASDAQ:SLP ) Q2 2025 Earnings Conference Call April 3, 2025 5:00 PM ET Company Participants Lisa Fortuna - IR, Financial Profiles Shawn O'Connor - CEO Will Frederick - CFO & COO Conference Call Participants David Larsen - BTIG Scott Schoenhaus - KeyBanc Capital Markets Matt Hewitt - Craig-Hallum Christine Rains - William Blair Jeff Garro - Stephens Constantine Davies - Citizen Operator Greetings, and welcome to the Simulations Plus Second Quarter Fiscal 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com 2025-04-04 00:44:34 Czytaj oryginał (ang.)
Simulations Plus (SLP) Tops Q2 Earnings and Revenue Estimates Simulations Plus (SLP) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.20 per share a year ago. zacks.com 2025-04-03 22:21:06 Czytaj oryginał (ang.)
Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its second quarter fiscal 2025, ended February 28, 2025. Second Quarter 2025 Financial Highlights (as compared to second quarter 2024) Total revenue increased 23% to $22.4 million Software. businesswire.com 2025-04-03 20:05:00 Czytaj oryginał (ang.)
Simulations Plus Gears Up for Q2 Earnings: What's in the Offing? SLP's fiscal Q2 2025 performance is likely to have benefited from continued momentum across its Software and Services segments amid budget constraints. zacks.com 2025-04-01 14:05:40 Czytaj oryginał (ang.)
Simulations Plus Announces Second Quarter Fiscal Year 2025 Earnings and Conference Call Date RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it will report second quarter fiscal 2025 financial results after the market close on Thursday, April 3, 2025. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discu. businesswire.com 2025-03-20 09:00:00 Czytaj oryginał (ang.)
Simulations Plus to Present at the KeyBanc Capital Markets Virtual Healthcare Investor Forum RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O'Connor, Chief Executive Officer, will be participating in a fireside chat at the KeyBanc Capital Markets Virtual Healthcare Investor Forum on Tuesday, March 18, 2025, at 2:15 p.m. Eastern Ti. businesswire.com 2025-03-10 09:00:00 Czytaj oryginał (ang.)
Simulations Plus to Participate in Upcoming Healthcare Investor Conferences RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it will participate in two healthcare investor conferences in February. The Company is attending the BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference taking p. businesswire.com 2025-02-04 09:30:00 Czytaj oryginał (ang.)
Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements RESEARCH TRIANGLE, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC). This partnership is aimed at advancing in vitro-in vivo correlation (IVIVC) approaches for oral drug delivery and expanding the function. businesswire.com 2025-01-22 09:50:00 Czytaj oryginał (ang.)
Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024 RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--SLP highlighted its impact on the pharma industry through support of the development of a majority of the drugs approved by the U.S. FDA in 2024. businesswire.com 2025-01-13 21:13:00 Czytaj oryginał (ang.)
Simulations Plus Supported Development of Every FDA-Approved Drug in 2024 RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--SLP highlighted its impact on the pharmaceutical industry through supporting the development of 100% of the drugs approved by the U.S. FDA in 2024. businesswire.com 2025-01-13 09:50:00 Czytaj oryginał (ang.)
Simulations Plus' Q1 Earnings Lag Estimates, Revenues Surge Y/Y SLP's fiscal first-quarter performance is driven by healthy revenue growth across its Software segment and contributions from the acquisition of Pro-ficiency. zacks.com 2025-01-08 10:31:10 Czytaj oryginał (ang.)
Simulations Plus, Inc. (SLP) Q1 2025 Earnings Call Transcript Simulations Plus, Inc. (NASDAQ:SLP ) Q1 2025 Earnings Conference Call January 7, 2025 5:00 PM ET Company Participants Lisa Fortuna - IR, Financial Profiles Shawn O'Connor - CEO Will Frederick - CFO & COO Conference Call Participants David Larsen - BTIG Francois Brisebois - Oppenheimer & Company Christine Rains - William Blair Scott Schoenhaus - KeyBanc Capital Markets Matt Hewitt - Craig-Hallum Jeff Garro - Stephens Operator Greetings, and welcome to the Simulations Plus First Quarter Fiscal 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com 2025-01-07 23:08:57 Czytaj oryginał (ang.)
Simulations Plus (SLP) Lags Q1 Earnings Estimates Simulations Plus (SLP) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.10 per share a year ago. zacks.com 2025-01-07 20:26:12 Czytaj oryginał (ang.)
Simulations Plus Reports First Quarter Fiscal 2025 Financial Results RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its first quarter fiscal 2025, ended November 30, 2024. First Quarter 2025 Financial Highlights (compared to first quarter 2024) Total revenue increased 31% to $18.9 million Software revenu. businesswire.com 2025-01-07 18:06:00 Czytaj oryginał (ang.)
3 Software Stocks to Keep an Eye on Amid Industry Headwinds Amid volatile macroeconomic conditions, Computer Software industry participants like ADSK, BB and SLP are well-poised to capitalize on digital transformation and strong adoption of cloud computing solutions. zacks.com 2025-01-07 16:00:52 Czytaj oryginał (ang.)
Simulations Plus Gears Up for Q1 Earnings: What's in Store? SLP's fiscal first quarter performance is likely to have gained from strength in both Software and Services' segments. zacks.com 2025-01-06 11:36:25 Czytaj oryginał (ang.)
Simulations Plus Announces First Quarter Fiscal Year 2025 Earnings and Conference Call Date RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that it will report first quarter fiscal 2025 financial results after the market close on Tuesday, January 7, 2025. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investm. businesswire.com 2024-12-17 18:06:00 Czytaj oryginał (ang.)
Wall Street Analysts Predict a 56.99% Upside in Simulations Plus (SLP): Here's What You Should Know The consensus price target hints at a 57% upside potential for Simulations Plus (SLP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com 2024-11-26 12:55:17 Czytaj oryginał (ang.)
Simulations Plus (SLP) Stock Jumps 8.9%: Will It Continue to Soar? Simulations Plus (SLP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. zacks.com 2024-11-22 10:16:09 Czytaj oryginał (ang.)
Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, in partnership with the University of Connecticut, was awarded a new FDA grant to investigate additional LAI product technologies. businesswire.com 2024-11-13 10:30:00 Czytaj oryginał (ang.)
How Much Upside is Left in Simulations Plus (SLP)? Wall Street Analysts Think 77.52% The consensus price target hints at a 77.5% upside potential for Simulations Plus (SLP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com 2024-11-08 12:55:20 Czytaj oryginał (ang.)
Simulations Plus to Participate in the Stephens Annual Investment Conference LANCASTER, Calif.--(BUSINESS WIRE)--Shawn O'Connor, CEO, will participate in a fireside chat at the Stephens Annual Investment Conference on Wednesday, November 20, 2024 at 12:00pm ET. businesswire.com 2024-11-06 10:30:00 Czytaj oryginał (ang.)
Simulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, with industry and academic partners, was awarded a new FDA grant to validate new methods for more efficient drug development. businesswire.com 2024-10-30 10:30:00 Czytaj oryginał (ang.)
Simulations Plus' Q4 Earnings Top Estimates on Solid Revenue Growth SLP's fiscal fourth-quarter performance is driven by healthy revenue growth across its software and services business segments. zacks.com 2024-10-24 14:46:27 Czytaj oryginał (ang.)
Simulations Plus, Inc. (SLP) Q4 2024 Earnings Call Transcript Simulations Plus, Inc. (SLP) Q4 2024 Earnings Call Transcript seekingalpha.com 2024-10-24 03:55:26 Czytaj oryginał (ang.)
Simulations Plus (SLP) Surpasses Q4 Earnings Estimates Simulations Plus (SLP) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.18 per share a year ago. zacks.com 2024-10-23 23:05:16 Czytaj oryginał (ang.)
Simulations Plus Announces Fourth Quarter and Fiscal Year 2024 Earnings and Conference Call Date LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host a conference call & webcast on October 23, 2024, at 5pm ET to discuss 4th quarter & fiscal year 2024 financial results. businesswire.com 2024-10-09 20:06:00 Czytaj oryginał (ang.)
Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery Offerings LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, in partnership with USC, is awarded a new research grant from the NIH to develop new AI-driven Drug Design methods. businesswire.com 2024-10-08 12:30:00 Czytaj oryginał (ang.)
Simulations Plus (SLP) Restructures Business Unit Post-Acquisitions Simulations Plus, Inc. SLP has streamlined its business unit and leadership structure to foster growth after recent acquisitions. These updates will be implemented on Aug 30, 2024. zacks.com 2024-08-26 16:00:49 Czytaj oryginał (ang.)
Simulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced strategic changes in leadership and the structure of its business units to optimize operations and support future growth. businesswire.com 2024-08-23 12:00:00 Czytaj oryginał (ang.)
Simulations Plus (SLP) Ties Up With ICCS for Chemical Safety Simulations Plus, Inc. SLP has entered into a partnership with the International Collaboration on Cosmetics Safety (“ICCS”) to develop a physiologically-based kinetic (PBK) read-across strategy for diverse chemicals and exposure routes (intravenous, oral and dermal) across virtual populations of humans and rodents. This collaboration aims to establish procedural workflows and guidelines for integrating these methods into animal-free safety assessments. zacks.com 2024-07-12 15:11:34 Czytaj oryginał (ang.)
Simulations Plus Stock Drops 15% Despite EPS Beat Simulations Plus NASDAQ: SLP is a small-cap healthcare technology company with a value of about $800 million. The firm has vastly underperformed the market and its sector over the last 12 months, with a total return of -7%. marketbeat.com 2024-07-05 13:12:05 Czytaj oryginał (ang.)
Simulations Plus (SLP) Q3 Earnings & Revenues Beat Estimates Simulations Plus' (SLP) fiscal third-quarter revenues are driven by strength in Software and Services units. zacks.com 2024-07-03 15:20:18 Czytaj oryginał (ang.)
Simulations Plus Posts Q3 Results, Joins First Foundation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session U.S. stock futures were lower this morning, with the Nasdaq futures falling around 0.2% on Wednesday. benzinga.com 2024-07-03 12:53:23 Czytaj oryginał (ang.)
Simulations Plus, Inc. (SLP) Q3 2024 Earnings Call Transcript Simulations Plus, Inc. (NASDAQ:SLP ) Q3 2024 Earnings Conference Call July 2, 2024 5:00 PM ET Company Participants Lisa Fortuna - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer & Chief Operating Officer Conference Call Participants Christine Rains - William Blair François Brisebois - Oppenheimer & Company Matt Hewitt - Craig-Hallum David Larsen - BTIG Operator Greetings, and welcome to the Simulations Plus Third Quarter Fiscal 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com 2024-07-02 23:28:10 Czytaj oryginał (ang.)
Analysts Estimate Simulations Plus (SLP) to Report a Decline in Earnings: What to Look Out for Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2024-06-25 15:00:30 Czytaj oryginał (ang.)